Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
<p>Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2018
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513566589059072 |
|---|---|
| author | Iman W. Achkar (4246141) |
| author2 | Nabeel Abdulrahman (725914) Hend Al-Sulaiti (14153271) Jensa Mariam Joseph (14151351) Shahab Uddin (154400) Fatima Mraiche (14151369) |
| author2_role | author author author author author |
| author_facet | Iman W. Achkar (4246141) Nabeel Abdulrahman (725914) Hend Al-Sulaiti (14153271) Jensa Mariam Joseph (14151351) Shahab Uddin (154400) Fatima Mraiche (14151369) |
| author_role | author |
| dc.creator.none.fl_str_mv | Iman W. Achkar (4246141) Nabeel Abdulrahman (725914) Hend Al-Sulaiti (14153271) Jensa Mariam Joseph (14151351) Shahab Uddin (154400) Fatima Mraiche (14151369) |
| dc.date.none.fl_str_mv | 2018-04-11T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12967-018-1471-1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Cisplatin_based_therapy_the_role_of_the_mitogen_activated_protein_kinase_signaling_pathway/21598440 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biochemistry and cell biology Biomedical and clinical sciences Medical biochemistry and metabolomics Cisplatin Mitogen activated protein kinase p90 ribosomal s6 kinase Combination therapy Synergy Apoptosis |
| dc.title.none.fl_str_mv | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.</p><h2>Other Information</h2> <p> Published in: Journal of Translational Medicine<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1186/s12967-018-1471-1" target="_blank">http://dx.doi.org/10.1186/s12967-018-1471-1</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_d4dd96bae3eaadabbb9e9b5c27b22884 |
| identifier_str_mv | 10.1186/s12967-018-1471-1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598440 |
| publishDate | 2018 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathwayIman W. Achkar (4246141)Nabeel Abdulrahman (725914)Hend Al-Sulaiti (14153271)Jensa Mariam Joseph (14151351)Shahab Uddin (154400)Fatima Mraiche (14151369)Biochemistry and cell biologyBiomedical and clinical sciencesMedical biochemistry and metabolomicsCisplatinMitogen activated protein kinasep90 ribosomal s6 kinaseCombination therapySynergyApoptosis<p>Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.</p><h2>Other Information</h2> <p> Published in: Journal of Translational Medicine<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1186/s12967-018-1471-1" target="_blank">http://dx.doi.org/10.1186/s12967-018-1471-1</a></p>2018-04-11T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12967-018-1471-1https://figshare.com/articles/journal_contribution/Cisplatin_based_therapy_the_role_of_the_mitogen_activated_protein_kinase_signaling_pathway/21598440CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215984402018-04-11T00:00:00Z |
| spellingShingle | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway Iman W. Achkar (4246141) Biochemistry and cell biology Biomedical and clinical sciences Medical biochemistry and metabolomics Cisplatin Mitogen activated protein kinase p90 ribosomal s6 kinase Combination therapy Synergy Apoptosis |
| status_str | publishedVersion |
| title | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| title_full | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| title_fullStr | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| title_full_unstemmed | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| title_short | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| title_sort | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
| topic | Biochemistry and cell biology Biomedical and clinical sciences Medical biochemistry and metabolomics Cisplatin Mitogen activated protein kinase p90 ribosomal s6 kinase Combination therapy Synergy Apoptosis |